A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
OncoResponse, Inc.
OncoResponse, Inc.
Massachusetts General Hospital
Maastricht University Medical Center
Genzada Pharmaceuticals USA, Inc.
Beijing Immunochina Medical Science & Technology Co., Ltd.
CureVac
Threshold Pharmaceuticals
National Cancer Institute (NCI)